title: Central neurocytoma: histologic atypia, proliferation potential, and clinical outcome.
abstract: BACKGROUND
  Although central neurocytomas are considered benign, recent reports suggest that some patients with histologic atypia and/or elevated proliferation potential may have a poor outcome.
  
  
  METHODS
  A retrospective review identified 15 cases of central neurocytoma. Clinical follow-up was available for 14 patients. Each tumor was evaluated for the presence of atypical histologic features, including cellular pleomorphism, endothelial proliferation, and necrosis. The proliferation potential was assessed by MIB-1 immunohistochemistry. The correlation among histology, MIB-1 labeling index (MIB-1 LI), and clinical outcome was evaluated.
  
  
  RESULTS
  Histologic atypia was identified in 3 tumors (20%). The MIB-1 LI ranged from 0.1% to 6.0%, and 5 cases (33%) had an MIB-1 LI >2%. The correlation between histologic atypia and MIB-1 LI was poor, with only 1 tumor having both atypia and MIB-1 LI >2%. Clinical follow-up ranged from 13 to 255 months postoperatively (mean, 68 months). Although most patients were alive and well at last follow-up, three developed symptomatic recurrence and one died as a result of increased tumor growth. The tumors from all 4 patients with a poor outcome had MIB-1 LI >2%, but only 1 had histologic atypia.
  
  
  CONCLUSIONS
  The proliferation potential of central neurocytoma is a useful predictor of clinical outcome, whereas histologic atypia alone is not prognostically significant. It would be appropriate to recognize a subgroup of central neurocytomas with elevated proliferation potential as WHO Grade 2 lesions. The terms "atypical" and "anaplastic" are not appropriate to describe these lesions, as they imply a certain histologic appearance. The most accurate designation would be "proliferating neurocytoma."
authors: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
authors: I R
authors: IR
authors: Mackenzie
mesh_terms: D000328:Adult; D034961:Antigens, Nuclear; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology*; D004727:Endothelium / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D018306:Neurocytoma / Q000401:mortality / Q000473:pathology*; D009687:Nuclear Proteins / Q000032:analysis; D012189:Retrospective Studies
chemical_list: D034961:Antigens, Nuclear; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009687:Nuclear Proteins